U.S. Markets closed

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VRAY, MYGN and CC

CEDARHURST, NEW YORK / ACCESSWIRE / October 16, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Viewray, Inc. (VRAY)

Investors Affected : March 15, 2019 - August 8, 2019

A class action has commenced on behalf of certain shareholders in Viewray, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (a) demand for ViewRay systems had declined due in part to changes being made to Medicare reimbursement approaches first announced in November 2019 that could make purchases of new ViewRay systems less profitable for customers; (b) the Company's reported backlog was overstated due to the inclusion of orders with insufficient surety as to permit for their inclusion in reported backlog; and (c) as a result of the foregoing, defendants' positive statements about ViewRay's business metrics and financial prospects during the Class Period were materially false and misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/viewray-inc-loss-submission-form/?id=3950&from=1

Myriad Genetics, Inc. (MYGN)

Investors Affected : September 2, 2016 - August 13, 2019

A class action has commenced on behalf of certain shareholders in Myriad Genetics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Myriad's product, GeneSight, lacked evidence or information sufficient to support the tests in their current form, including their purported benefits; (ii) the U.S. Food and Drug Administration ("FDA") had requested changes to GeneSight and questioned the validity of the test's purported benefits; (iii) Myriad had been in ongoing discussions with the FDA regarding the FDA's requested changes to GeneSight; (iv) Myriad's acquisition of Counsyl-and thereby, Foresight-caused the Company to incur the risk of suffering from lower reimbursement for its expanded carrier screening tests, which had the potential to, and actually did, materialize into a material negative impact on the Company's revenue; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/myriad-genetics-inc-loss-submission-form/?id=3950&from=1

The Chemours Company (CC)

Investors Affected : February 16, 2017 - August 1, 2019

A class action has commenced on behalf of certain shareholders in The Chemours Company. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Chemours had not appropriately accounted and accrued reserves for its environmental liabilities; (2) the possibility of costs exceeding accrued amounts was greater than the Company had represented to a point that could be material; (3) the Company's policies, standards and procedures were not properly designed to prevent unreasonable risk of harm to people and the environment (4) Chemours' handling, manufacture, use, and disposal of hazardous substances was not in accordance with applicable environmental laws and regulations; and (5) as a result of these misrepresentations, Chemours shares traded at artificially inflated prices.

Shareholders may find more information at https://kclasslaw.com/securities/the-chemours-company-loss-submission-form/?id=3950&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC



View source version on accesswire.com:
https://www.accesswire.com/563257/FILING-DEADLINE-Kuznicki-Law-PLLC-Announces-Class-Actions-on-Behalf-of-Shareholders-of-VRAY-MYGN-and-CC